Genocea Biosciences Inc P/FCF
Cos'è P/FCF di Genocea Biosciences Inc?
P/FCF di Genocea Biosciences Inc è 0.00
Qual è la definizione di P/FCF?
Il prezzo del flusso di cassa libero (P/FCF) è una metrica di valutazione che mette a confronto il prezzo corrente delle azioni della società con il suo flusso di cassa disponibile per azione.
Price to free cash flow (P/FCF) is a measure that value investors find useful to analyze a company’s finances in relation to its current stock price. It is a stricter measure than the price to cash flow ratio as it subtracts capital expenditures from cash flow.
Free cash flow relies heavily on the state of a company's cash from operations, which is in turn heavily influenced by the company's net income. Companies can manipulate their free cash flow by lengthening the time they take to pay their bills, shortening the time it takes to collect what's owed to them, and putting off buying inventory. It also depends on what items are considered capital expenditures and this can be different in case of different companies.
Lower values of P/FCF generally indicate a company that is undervalued and whose stock is relatively cheap in relation to its free cash flow. Conversely, higher P/FCF indicate that the company's stock is relatively overvalued. Value investors thus favor companies with low or decreasing price to free cash flow values that indicate high or increasing free cash flow totals and relatively low stock share prices.
It is best to compare price to free cash flow ratios between similar companies in the same industry. However, the P/FCF metric can also be viewed over a longer time frame to see if the company's cash flow to share price value is improving or declining.
P/FCF di aziende nel Health Care settore su NASDAQ rispetto a Genocea Biosciences Inc
Cosa fa Genocea Biosciences Inc?
Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Aziende con p/fcf simili a Genocea Biosciences Inc
- Genocea Biosciences Inc ha P/FCF di 0.00
- Enel Generacion Chile S.A ha P/FCF di 0.01
- Enel Generacion Chile S.A ha P/FCF di 0.01
- YPF ha P/FCF di 0.01
- Mallinckrodt plc ha P/FCF di 0.01
- Frontier Communications ha P/FCF di 0.01
- Monitronics International ha P/FCF di 0.01